Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Depreciation & Amortization (CF) (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $81000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 14.08% to $81000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $240000.0 through Dec 2025, down 31.82% year-over-year, with the annual reading at $240000.0 for FY2025, 31.82% down from the prior year.
  • Depreciation & Amortization (CF) hit $81000.0 in Q4 2025 for Aptevo Therapeutics, up from $49000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $299000.0 in Q2 2021 to a low of $49000.0 in Q2 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $160200.0 across 5 years, with a median of $136500.0 in 2023.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 14.08% in 2025; the steepest drop was 46.15% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $256000.0 in 2021, then tumbled by 37.11% to $161000.0 in 2022, then dropped by 27.95% to $116000.0 in 2023, then crashed by 38.79% to $71000.0 in 2024, then increased by 14.08% to $81000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for APVO at $81000.0 in Q4 2025, $49000.0 in Q3 2025, and $49000.0 in Q2 2025.